Either anti-ICOS treatment or IL-21 neutralization in GVHD-SSc mice inhibited inflammation and dermal fibrosis, suggesting that inhibition of ICOS and IL-21 might have therapeutic benefits for the treatment of SSc [115]. The gene discussed is IL21; the disease is graft versus host disease.